Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5123—Organic compounds, e.g. fats, sugars
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/45—Transferases (2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
  • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
  • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
  • C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
  • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
  • C07C323/26—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
  • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
  • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
  • C07D209/16—Tryptamines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
  • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/02—Boron compounds
  • C07F5/025—Boronic and borinic acid compounds
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/11—Antisense
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2320/00—Applications; Uses
  • C12N2320/30—Special therapeutic applications
  • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

• CNS central nervous systems
• BBB blood-brain-barrier
• small molecule drugs and macromolecules e.g., peptides, gene drugs, and protein drugs
• BBB blood-brain-barrier
• direct administration to the CNS is invasive, which may cause infection and tissue damage, and is also limited by diffusion distance and rapid efflux of drugs out of the CNS within hours.
• BBB-impermeable cargos in particular for gene and nucleic acid therapy, into CNS remain to be desired.
• the carrier vehicle mediated brain drug delivery is considered a promising and versatile brain delivery system.
• various carrier vehicles such as viral vectors, exosomes, molecular Trojan horses and sundry nanoparticle formulations, have been developed to enhance brain delivery.
• Viral vectors are effective for gene delivery to brain, but have limitations such as production cost and safety concerns.
• Exosomes have been utilized to deliver small molecules, proteins and nucleic acids to the brain due to their non- immunogenic nature; however, there still exist many challenges in the isolation methods, cargo loading procedure, in vivo toxicity and pharmacokinetics.
• the molecular Trojan horse approach relying on the receptor-specific monoclonal antibodies or peptides to ferry the genetically fused cargo into the brain, is promising in delivery of biologies across the BBB.
• the manufacturing process needs to be tailored specifically for each for different biologic cargo, and the stability, safety and immunogenicity are challenge to clinical development.
• Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles and nanocapsules have shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure the particles produced are BBB-permeable.
• Neuro transmitters are endogenous chemicals that enable neurotransmission.
• neurotransmitters have been demonstrated to cross the BBB.
• dimethyltryptamine and other tryptamine derivatives have been shown to cross the BBB by active transport across the endothelial plasma membrane.
• Y is a moiety derived from a neurotransmitter
• W is -NR 20 -, -0-, or -S-;
• R Lipid independently substituted or unsubstituted C 1 -20 alkyl, substituted or unsubstituted C 1 -20 alkenyl, substituted or unsubstituted C 1 -20 alknyl, substituted or unsubstituted C 1 -20 heteroalkyl, substituted or unsubstituted C 1 -20 heteroalkenyl, or substituted or unsubstituted C 1 -20 heteroalknyl; and R 20 is R Lipid , H, C 1-6 alkyl, C 1-6 alkenyl, or C 1-6 alkynyl.
• lipidoid nanoparticles comprising a compound disclosed herein.
• pharmaceutical compositions comprising a lipidoid nanoparticle disclosed herein; and a pharmaceutically acceptable carrier or excipient.
• Fig. 1 A is a schematic illustration of formulating NT-lipidoid doped LNPs for cargo delivery to brain.
• Fig IB is a schematic illustration of synthesis route, lipid nomenclature, and chemical structure of neurotransmitters used for lipidoid synthesis.
• Fig 1C is a representative ex vivo fluorescence images of the dissected brain 1 h after one-time intravenous injection of 1 mg kg -1 DiR-labeled NT-LNPs. DiR was doped into the NT-LNPs with a 10% weight ratio. The mice were perfused with saline before dissection.
• Fig 2A is chemical structure of PBA-Q76-O16B, NT1-O12B, and schematic illustration of the doped NT1 -lipidoid AmB formulation.
• Fig. 2B are photographs of AmB formulations in NT1-O12B doped with different amounts of PBA-Q76O16B (weight ratio is used).
• the pure NT1-O12B/AmB encapsulates appeared as an opaque suspension, while the appearance of the encapsulates changed from translucent solutions to homogenous transparent yellow solutions as the doping ratio of PBA-Q76-O16B lipidoid increased,
• Fig. 2C is graph depicting hydrodynamic diameters and polydispersity indexes of different NT-LNP /AmB formulations determined by DLS measurements.
• Fig. 2D are representative fluorescence images of the dissected mouse brain 1 h after one-time intravenous injection of 1 mg kg -] DiR-loaded NT1-O12B/PBA-Q76-O16B LNPs. The weight ratio of DiR in LNPs is 10%.
• Fig. 3A shows chemical structures of 306-O12B-3, NT1-O14B, and schematic illustration of the doped NT-lipidoid Tau-ASOO formulation for brain delivery.
• Fig. 3B is a graph depicting GFP silencing efficiency of HEK-GFP cells treated with or without ASO/NT -LNPs complexes.
• the NT1-O14B LNPs alone showed no silencing efficacy, while doping NT1-lipidoid into 306-012B-3 LNPs led to successful gene silencing in vitro. * ⁇ 0.01 vs. all other samples in the same group.
• Fig. 4A is a schematic illustration of mixed LNP formulation using NT1-O14B and PBA-Q76-016B for GFP-Cre protein delivery into brain.
• Fig. 4B are fluorescence images of the brain slices of Ail4 mice treated with (- 27)GFP-Cre in different LNP formulations.
• Fig. 5 are TEM images ofNT1-LNPs and table of hydrodynamic sizes, polydispersity index, zeta potential.
• Fig. 6 is graph summarizing relative fluorescence intensity of the dissected brain tissue 1 h after one-time intravenous injection of 1 mg kg-1 DiR-labeled NT-LNPs. DiR was doped into the NT-LNPs with a 10% weight ratio. The mice were perfused with saline before dissection. One-way ANOVA, Sidak post hoc analysis, *p ⁇ 0.05 or **p ⁇ 0.01.
• Fig. 7 are representative ex vivo fluorescence images of the dissected brain 1 h after one-time intravenous injection of 1 mg kg-1 DiR-labeled LNPs or NT1-O12B doped NTLNPs (ratio 3:7, w/w), and the chemical structure of 76-O16B, EC 16-80, and 113- O16B, DiR was doped into the NT-LNPs with a 10% weight ratio. The mice were perfused with saline before dissection. [0027] Fig.
• Fig. 9 is a graph depicting AmB concentration in brain tissues 24 h after intravenous injection of 5 mg/kg AmB in various NT1 derivatives measured using HPLC. The mice were perfused with saline before dissection.
• Fig. 10A is a photograph of AmB formulations in NT1-lipidoids with different tail lengths (018B, O16B, O14B, O12B). All four NT1 /AmB encapsulates showed opaque suspension.
• Fig. 10B is a graph depicting hydrodynamic diameters and polydispersity indexes of NT-LNPs determined by DLS measurements.
• Fig. 11 is a TEM image of NT1-O12B/PBA-Q76O16B-3/7-AmB complex, and a table that summarizes hydrodynamic sizes, polydispersity index, zeta potential, and DLC of AmB/NT-LNPs complex.
• Fig. 12 is a graph that summarizes relative fluorescence intensity of the dissected brain tissue lh after one-time intravenous injection 1 mg kg —1 DiR-loaded NT1- O12B/PBA-Q76-O16B LNPs. The weight ratio of DiR in LNPs is 10%. **p ⁇ 0.001. Oneway ANOVA, Sidak post hoc analysis.
• Fig. 13 is a calibration curve of AmB concentration dissolved in methanol ranging from 0.005 to 0.5 ug/mL (low concentration), or 0.007 to 3.0 ug/mL (high concentration) at 415 nm by HPLC.
• Fig. 14 is mAU-time graphs of AmB concentrations in brain tissues 24h after intravenous treatment with NT1 -Ol 2B/PBA-Q76016-LNPs (ratio: 3/7)- AmB complex at a single dose of 5 mg AmB/kg by HPLC.
• Fig. 15 are graphs depicting AmB concentrations in other organs 24 h after intravenous injection of 5 mg/kg AmB measured by HPLC.
• Fig. 16 is TEM images of blank and ASO loaded NT1 -O14B/306-012B-3 (ratio: 3/7) nanoparticles and a table o f hydro dynamic sizes, polydispersity index, zeta potential
• Fig. 17 are TEM images of blank and (-27)GFP-Cre loaded NT1-O14B/PBA- Q76O16B (ratio: 3/7) nanoparticles and a table of hydrodynamic sizes, polydispersity index, zeta potential.
• Fig. 18A is a scheme that depicts the synthesis of IE tail.
• Fig. 1SB is a scheme that depicts the synthesis of PBA-Q76O16B and PBA- Q80O16B.
• Fig. 18C is a scheme that depicts the synthesis of NT1-Neu.
• Figs. 19A-19N are fluorescence images of section of Ail4 mouse brain.
• the mouse were injected with Cre mRNA complexed with Dlin-MC3Z NT1-O14B LNP.
• the LNP formulation was described in slide 1.
• Figs. 20A-20B are fluorescence images of section of Ail 4 mouse brain. The mice were injected with Cre mRNA complexed with PBA-Q76O16B/NT1-O14B LNP. The LNP formulation was described in slide 1.
• Figs. 21A-21B are fluorescence images of section of Ail4 mouse brain. The mice were injected with Cre mRNA complexed with Dlin-MC3ZNT1-O14B LNP. The LNP formulation was described in slide 1.
• Y is a moiety derived from a neurotransmitter
• W is -NR 20 -, -0-, or-S-;
• R Lipid independently substituted or unsubstituted C 1 -20 alkyl, substituted or unsubstituted C 1 -20 alkenyl, substituted or unsubstituted C 1 -20 alknyl, substituted or unsubstituted C 1 -20 heteroalkyl, substituted or unsubstituted C 1 -20 heteroalkenyl, or substituted or unsubstituted C 1 -20 heteroalknyl; and R 20 is R Lipid , H, C 1-6 alkyl, C 1-6 alkenyl, or C 1-6 alkynyl.
• Y is selected from:
• Y is
• W is -NR 20 - or -S-. In certain embodiments, W is -NR 20 -, In certain embodiments, W is -S-.
• W is -NR 20 -, and R 20 is R Lipid .
• W is -NR 20 -
• R 20 is R Lipid
• Y is
• R Lipid is of the structure: wherein: each instance of R 1 and R 2 is independently -H, -OH, -NHR 30 , or -SH;
• X and Y are independently -CH 2 -, -NR 30 -, -O-, -S-, or -Se-; m is an integer selected from 1-3; n is an integer selected from 1-14; p is 0 or 1; q is an integer selected from 1-10; t is 0 or 1; and
• R 30 is -H, C 1-6 alkyl, C 1-6 alkenyl, or C 1-6 alkynyl.
• each instance of R 1 and R 2 is independently -H or -OH.
• R 1 and R 2 are -H.
• R 1 is -H; and R 2 is -OH.
• R 3 and R 4 are -H.
• Z is -CH 2 -, -0-, or -NR 30 -, In certain embodiments, Z is -
• Z is -0-. In certain embodiments, Z is -NR 30 -.
• R 1 is -H
• R 2 is -OH
• R 3 and R 4 are -H
• Z is -CH 2 -.
• X and Y are independently -CH 2 - or -O-. In certain embodiments, X and Y are independently -CH 2 - or -O-, wherein X and Y are not the same. In certain embodiments, X and Y are independently -CH 2 - or -S-. In certain embodiments, X and Y are both -CH 2 -. In certain embodiments, X and Y are both -S-.
• n is 1 or 2. In certain embodiments, m is 1. In certain embodiments, m is 2.
• n is an integer selected from 4-12. In certain embodiments, n is an integer selected from 6-10.
• p is 0. In certain embodiments, p is 1.
• q is an integer selected from 2-8. In certain embodiments, q is an integer selected from 4-8.
• t is 0, In certain embodiments, t is 1.
• the compound is selected from the group consisting of:
• lipidoid nanoparticles comprising a compound disclosed herein.
• the nanoparticle disclosed herein further comprising a protein.
• the protein is GFP-Cre.
• the nanoparticle disclosed herein further comprises a nucleic acid.
• the nucleic acid is Tau-ASOs.
• the nanoparticle disclosed herein further comprises a small molecule.
• the small molecule is an antifungal agent or a chemotherapeutic agent.
• the small molecule is selected from the group consisting of bortezomib, imatinib, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, daunorubicin hydrochloride, cytarabine, fluorouracil, irinotecan hydrochloride, vincristine sulfate, methotrexate, paclitaxel, vincristine sulfate, epirubicin, docetaxel, cyclophosphamide, carboplatin, lenalidomide, ibrutinib, abiraterone acetate, enzalutamide, pemetrexed, palbociclib, nilotinib, everolimus, ruxolitinib, epirubicin, pirirubicin, idarubicin, valrubicin, amrubicin,
• the small molecule is amphotericin B or doxorubicin.
• the lipidoid nanoparticle has a particle size of about 25 nm to about 1000 nm. In certain embodiments, the lipidoid nanoparticle has a particle size of about 50 nm to about 500 nm.
• compositions comprising a lipidoid nanoparticle disclosed herein; and a pharmaceutically acceptable carrier or excipient.
• the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not.
• “optionally substituted alkyl” refers to the alkyl may be substituted as well as where the alkyl is not substituted.
• substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skilled person in the art to result chemically stable compounds which can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials, If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
• the term “optionally substituted” refers to the replacement of one to six hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH 2 -O-alkyl, -0P(O)(0-alkyl) 2 or -CH 2 -0P(O)(0-alkyl) 2 .
• “optionally substituted” refers to the replacement of one to four hydrogen radicals in a given structure with the substituents mentioned above. More preferably, one to three hydrogen radicals are replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.
• Articles such as “a, " “ an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
• the invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
• the invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
• alkyl refers to saturated aliphatic groups, including but not limited to C 1 -C 10 straight-chain alkyl groups or C 1 -C 10 branched-chain alkyl groups.
• the “alkyl” group refers to C 1 -C 6 straight-chain alkyl groups or C 1 -C 6 branched- chain alkyl groups.
• the “alkyl” group refers to C 1 -C 4 straight-chain alkyl groups or C 1 -C 4 branched-chain alkyl groups.
• alkyl examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1 -pentyl, 2- pentyl, 3-pentyl, neo-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 4- heptyl, 1 -octyl, 2-octyl, 3 -octyl or 4-octyl and the like.
• the “alkyl” group may be optionally substituted.
• acyl is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.
• acylamino is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.
• acyloxy is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)0-, preferably alkylC(O)0-.
• alkoxy refers to an alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like. [0086]
• alkoxyalkyl refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O- alkyl.
• alkyl refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.
• a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1-30 straight chains, C 3-30 for branched chains), and more preferably 20 or fewer.
• alkyl as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.
• C x-y or “C x -C y ”, when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain.
• Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal.
• a C 1-6 alkyl group for example, contains from one to six carbon atoms in the chain,
• alkylamino refers to an amino group substituted with at least one alkyl group.
• alkylthio refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.
• amide refers to a group
• R 9 and R 10 each independently represent a hydrogen or hydrocarbyl group, or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
• amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by
• R 9 , R 10 , and R 10 ’ each independently represent a hydrogen or a hydrocarbyl group, or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.
• aminoalkyr refers to an alkyl group substituted with an amino group.
• aralkyl refers to an alkyl group substituted with an aryl group.
• aryl as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon.
• the ring is a 5- to 7- membered ring, more preferably a 6-membered ring.
• aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
• Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
• R 9 and R 10 independently represent hydrogen or a hydrocarbyl group.
• the term “carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, un saturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings.
• the term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring.
• Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings.
• an aromatic ring e.g., phenyl
• a saturated or unsaturated ring e.g., cyclohexane, cyclopentane, or cyclohexene.
• Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane.
• Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo [4.2.0] octane, 4, 5,6,7- tetrahydro-lH-indene and bicyclo[4.1 ,0]hept-3-ene.
• “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.
• Carbocyclylalkyl refers to an alkyl group substituted with a carbocycle group.
• carbonate is art-recognized and refers to a group -OCO 2 -.
• esters refers to a group -C(O)0R 9 wherein R 9 represents a hydrocarbyl group.
• ether refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O- heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl,
• halo and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.
• heteroaryl refers to an alkyl group substituted with a hetaryl group.
• heteroaryl and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6- membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
• heteroaryl and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
• Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
• heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
• heterocyclylalkyl refers to an alkyl group substituted with a heterocycle group.
• heterocyclyl refers to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
• heterocyclyl and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
• Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
• Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.
• hydroxy alkyl refers to an alkyl group substituted with a hydroxy group.
• lower when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer.
• acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).
• polycyclyl refers to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”.
• Each of the rings of the polycycle can be substituted or unsubstituted.
• each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.
• sulfate is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.
• R 9 and R 10 independently represents hydrogen or hydrocarbyl.
• sulfoxide is art-recognized and refers to the group-S(O)-.
• sulfonate is art-recognized and refers to the group SO3H, or a pharmaceutically acceptable salt thereof,
• substituted refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds.
• the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
• the permissible substituents can be one or more and the same or different for appropriate organic compounds.
• the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
• Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamide, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety.
• thioalkyl refers to an alkyl group substituted with a thiol group.
• thioester refers to a group -C(O)SR 9 or -SC(O)R 9 [0127] wherein R 9 represents a hydrocarbyl.
• thioether is equivalent to an ether, wherein the oxygen is replaced with a sulfur.
• urea is art-recognized and may be represented by the general formula
• R 9 and R 10 independently represent hydrogen or a hydrocarbyl.
• the term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.
• pharmaceutically acceptable is art-recognized.
• the term includes compositions, excipients, adjuvants, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• Salt is used herein to refer to an acid addition salt or a basic addition salt.
• stereogenic center in their structure.
• This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30.
• the disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.gchev WO 01/062726.
• “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
• “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
• such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
• such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentaneprop ionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethane-disulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, chlorobenzenesulfonic acid, 2- naphthalenesulfonic acid, 4-toluenesulfonic
• Salts further include, by way of example only, sodium potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of nontoxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
• pharmaceutically acceptable cation refers to an acceptable cationic counterion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like (see, e. g., Berge, et al., J. Pharm. Sci. 66 (1):1-79 (January 77).
• “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
• “Pharmaceutically acceptable metabolically cleavable group” refers to a group that is cleaved in vivo to yield the parent molecule of the structural formula indicated herein.
• Examples of metabolically cleavable groups include -COR, -COOR, -CONRR and -CH 2 OR radicals, where R is selected independently at each occurrence from alkyl, trialkylsilyl, carbocyclic aryl or carbocyclic aryl substituted with one or more of alkyl, halogen, hydroxy or alkoxy.
• Specific examples of representative metabolically cleavable groups include acetyl, methoxycarbonyl, benzoyl, methoxymethyl and trimethylsilyl groups.
• Prodrugs refers to compounds, including derivatives of the compounds of the invention, which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N- alkylmorpholine esters and the like. Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
• Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides.
• Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particular prodrugs.
• double ester type prodrugs such as (acyloxy)alkyl esters or (alkoxycarbonyl)oxy)alkyl esters.
• C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, C 7 -C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds of the invention are particularly the C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, C 7 -C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds of the invention.
• Solvate refers to forms of the compound that are associated with a solvent or water (also referred to as “hydrate”), usually by a solvolysis reaction. This physical association includes hydrogen bonding.
• solvents include water, ethanol, acetic acid and the like.
• the compounds of the invention may be prepared e.g., in crystalline form and may be solvated or hydrated.
• Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
• “Solvate” encompasses both solution-phase and isolab le solvates. Representative solvates include hydrates, ethanolates and methanolates.
• a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle aged adult or senior adult) and/or a non- human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs.
• the subject is a human.
• the subject is a non-human animal.
• the terms “human,” “patient,” and “subject” are used interchangeably herein,
• an “effective amount” means the amount of a compound that, when administered to a subject for treating or preventing a disease, is sufficient to effect such treatment or prevention.
• the “effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.
• a “therapeutically effective amount” refers to the effective amount for therapeutic treatment.
• a “prophylatically effective amount” refers to the effective amount for prophylactic treatment.
• Preventing or “prevention” or “prophylactic treatment” refers to a reduction in risk of acquiring or developing a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject not yet exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset,
• prophylaxis is related to “prevention,” and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease.
• prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization, and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
• Treating” or “treatment” or “therapeutic treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof).
• “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject.
• “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
• “treating” or “treatment” relates to slowing the progression of the disease.
• isotopic variant refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound.
• an “isotopic variant” of a compound can contain one or more non-radioactive isotopes, such as for example, deuterium ( 2 H or D), carbon- 13 ( 13 C), nitrogen- 15 ( 15 N), or the like.
• the following atoms, where present, may vary, so that for example, any hydrogen may be “ 2 H/D, any carbon may be 13 C, or any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art.
• the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies.
• the radioactive isotopes tritium, i.e., 3 H, and carbon- 14, i.e., 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
• com pounds may be prepared that are substituted with positron emitting isotopes, such as 11 C, 18 F, 15 0 and 13 N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
• PET Positron Emission Topography
• enantiomers Stereoisomers that are not mirror images of one another are termed “diastcrcomcrs” and those that are non-super imp osable mirror images of each other are termed “enantiomers.”
• a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
• An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R - and S - sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+)- or (-)- isomers respectively).
• a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
• Tautomers refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of it electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro-forms of phenylnitromethane, that are likewise formed by treatment with acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest,
• a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess).
• an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form.
• enantiomerically pure or “pure enantiomer” denotes that the compound comprises more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer.
• the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
• the term “enantiomerically pure R- compound” refers to at least about 95% by weight R-compound and at most about 5% by weight S-compound, at least about 99% by weight R-compound and at most about 1% by weight S-compound, or at least about 99.9 % by weight R-compound and at most about 0, 1% by weight S-compound. In certain embodiments, the weights are based upon total weight of compound.
• the term “enantiomerically pure S- compound” or “S-compound” refers to at least about 95% by weight S-compound and at most about 5% by weight R-compound, at least about 99% by weight S-compound and at most about 1% by weight R-compound or at least about 99.9% by weight S-compound and at most about 0.1% by weight R-compound. In certain embodiments, the weights are based upon total weight of compound.
• an enantiomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof can be present with other active or inactive ingredients.
• a pharmaceutical composition comprising enantiomericEdly pure R-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R-compound.
• the enantiomerically pure R-compound in such compositions can, for example, comprise at least about 95% by weight R-compound and at most about 5% by weight S-compound, by total weight of the compound.
• a pharmaceutical composition comprising enantiomerically pure S-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S-compound.
• the enantiomericEdly pure S-compound in such compositions can, for example, comprise, at least about 95% by weight S-compound and at most about 5% by weight R-compound, by total weight of the compound.
• the active ingredient can be formulated with little or no excipient or carrier.
• the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.
• heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.
• the (-27)GFP-Cre (addgene #89253) protein were expressed and extracted from BL21 E.coli , and further purified by Ni-NTA column (Qiagen). Nanoparticle size and ⁇ potential were recorded on ZetaPALS particle size analyzer. TEM images were captured by a FEI Technai Spirit Transmission Electron Microscope, Livid Synthesis
• All head amines used for lipid synthesis are commercially available from Sigma- Aldrich. All the cationic lipidoids (NT1-O12B-018B, NT2-O12B-018B, NT3- O12B-018B, NT1 -EC 16, NT1-C18, NT1-1E, NT2-EC16, NT2-1E, NT3-EC16, NT3-1E, 306-012B-3, 76-016B) were synthesized according to our previous reports. The crude product was purified using flash chromatography on silica gel. The IE tail was synthesized as shown in Fig. 18A. The phenylboronic acid quatemized lipidoids were synthesized as shown in Fig. 18B. NT1-Neu was synthesized as shown in Fig. 18C. The lipid structure was confirmed using 1H NMR and electrospray ionization (ESI) MS.
• ESI electrospray ionization
• NT-lipidoids and DiR is dissloved at a weight ratio of 10:1, together in 100% ethanol. 100 ⁇ L solution was then added dropwise to 300 ⁇ L of sodium acetate buffer (25 mM, pH 5.2) and vortexed briefly. Finally, we removed the ethanol in the formulation by dialysis against diH20 (MWCO 35 kDa, ThermoFisher) for 12 h. Then the DiR-labelled LNPs were intravenously injected into BALB/C mice (female, 6 weeks age). After 1 hour, mice were anesthetized and perfused with saline. Afterward, mice brains were collected. The fluorescent signals distribution was visualized using the Spectrum CT Biophotonic Imager (PerkinElmer, Boston, MA).
• the AmB encapsulates were prepared according to our previous report.3 Briefly, 1 mg each lipidoid (solid) was mixed with 1 mg AmB in 300 ⁇ L Dimethyl sulfoxide (DMSO). The mixtures were sonicated for 30 min and then vortexed for 10 min until completely dissolved. The solution was added drop wise to a glass bottle containing 600 ⁇ L sodium acetate buffer (pH 5.0) with continuous homogenization at 700 rpm. The solutions were further dialyzed against distilled water to remove DMSO and non-encapsulated AmB using dialysis tubing (MWCO 35 kDa) overnight.
• DMSO Dimethyl sulfoxide
• NT-lipidoids synthesis and BBB-permeabilitv study of the NT-LNPs [0166] N eurotransmitters tryptamine, phenethylamine, and phenylethanolamine were selected as the structural basis of the synthetic lipidoids.
• the NT-lipidoids were synthesized through Michael addition between the primary amine of the neurotransmitters and acrylate- containing hydrophobic tails in glass vials at 70 °C for 48 h (Fig. IB), using an approach similar to our previously published combinatorial lipid library synthesis strategy. The result is a combinatorial library of NT-lipidoids, each containing one particular neurotransmitter as the head group, and one particular bioreducible hydrophobic structure as the tail group.
• NT1-O12B indicates a lipidoid containing a tryptamine head group, and a hydrophobic tail group containing 12 carbon atoms. All the NT-lipidoids were purified using flash chromatography and characterized by ESI-MS (Fig. 5).
• NT-lipidoids are amphiphilic, and thus are capable of self-assembly into either micelles or liposomes when prepared in aqueous solution.
• DiR fluorescent dye
• the NT-lipidoid and DiR were mixed in ethanol in a 10/1 (w/w) ratio, added the mixture dropwise to sodium acetate buffer (25 mM, pH 5,2), and then removed the ethanol through dialysis.
• the DiR-loaded NT-lipidoid nanoparticle solution was injected into mouse via tail vein injection. After 1 h, the animals were sacrificed and perfused with saline. The skull was removed, and the brain was imaged using an I VIS imaging device (PerkinElmer) at the excitation wavelength of 750 nm.
• Fig. 1C strong DiR fluorescence signal is observed in the mouse brain treated with DiR/NT1-lipidoid nanoparticles, compared to the mouse brain treated with DLR/NT2-lipidoids and DLR/NT3-lipidoids where the fluorescent signal was very weak. It is also observed that length of the aliphatic tail chain significantly influenced the observed fluorescent intensity, with NT1-lipidoids containing a shorter aliphatic chain length resulting in a greater fluorescence intensity (Fig. 7). There is no significant difference of the physical properties, such as hydrodynamic sizes, polydispersity index, zeta potential, and morphologies between these NT1 derived lipidoids (Fig. 6).
• NT1-lipidoids such as NT1-O12B into other BBB- impermeable lipid formulations led to the resulting lipid formulation crossing the BBB.
• NT1 The chemical structure of NT1 is based on the neurotransmitter dimethyltryptamine which has been reported to cross the BBB by active transport across the endothelial plasma membrane. 21 It is hypothesized that our results are also driven by active transport, and that changes in the chemical structure of the NT 1 lipid would modulate its ability to cross the BBB. We hypothesized specifically that the ionizability of the a-amine in the tryptamine (NT1) after the lipidization is an important factor for the derivatives to cross BBB. To verify this hypothesis, a series of NT1 derivatives with different linkers were synthesized, as shown in Fig. 9.
• the DiR signals were observed from the mouse brain treated with all NT1 derivatives except NT1-neu, In NT1-neu, the a-amine in the tryptamine is connected through an amide bond, not ionizable, while the ⁇ -amine in other NT1 derivatives are all ionizable. Further, no strong DiR signals were observed from the mouse brain treated with NT2 and NT3 derived lipidoids with any linkers.
• NT1 derived lipidoids are identified to be able to deliver a hydrophobic dye (DiR) into brain, either when used alone or when doped into other LNPs. Delivering therapeutically relevant hydrophobic drug molecules into brain was examined using these NT1 -derived lipidoids.
• Amphotericin B ( AmB) was chosen as a model drug. AmB is a classic polyene antifungal drug and is the gold standard for the treatment of severe systemic fungal infections. However, it cannot be used clinically for the treatment of brain fungal infections due to its BBB-impermeability.
• AmB was encapsulated in pure NT1 -lipidoids (namely NT1-O12B, NT1-O14B, NT1-Q16B, and NT1-018B) using a procedure similar to the DiR encapsulation.
• the AmB loaded NT1-lipidoid nanoparticles were injected into mice via tail vein at a dose of 5 mg/kg AmB per mouse. After 24hr, animals were sacrificed, and the brains were harvested, perfused with saline, and homogenized. The AmB concentration in brain tissue was quantified using HPLC (detailed methods are in SI). As shown in Fig.
• the AmB concentration in the brain tissue of all the four groups was around 150 ng/g tissue, Notably, in our previous report, AmB was undetectable in the brain after systemic delivery with traditional synthetic lipidoids, indicating the NT1-lipidoid formulations enhanced the AmB delivery to the mouse brain.
• the AmB formulated in NT-lipidoid formulation showed opaque solution (Fig. 11 A), indicating the large size of the particles in the solution.
• DLS results (Fig. 11B, Fig. 12) showed that the nanoparticles are in range of 750-800 nm in diameter. It is hypothesized that making NT1-lipidoid nanoparticle smaller may help improve the brain delivery efficiency.
• the quatemized lipidoids provided stable AmB formulation with smaller particle size, comparing with the non- quatemized lipids. 27
• doping a quatemized lipidoid with NT1- lipidoid may result in a smaller nanoparticle size while maintaining or improving the ability to penetrate the BBB.
• a new phenylboronic acid quatemized lipidoid was synthesized, PBA-Q76- O16B (Fig. 2A) for AmB encapsulation.
• NT1-O12B was chosen as the dopant for enhanced brain delivery since it showed the highest DiR fluorescence intensity (Fig. 1C) among all NT lipidoids.
• the AmB was formulated in the mixture ofNT1-O12B and PBA-Q76-O16B, with the two lipidoids mixed at different weight ratios (7:3, 5:5, 3:7, 1 :9, and pure PBA- Q76-O16B). As shown in Fig.
• the AmB delivery using the mixed lipids was further studied and determined the AmB concentration in the mice brain tissue 24hr after intravenous injection of 5 mg/kg AmB per mouse. As shown in Fig. 2E, the amount of AmB detected in the brain increased as the doping ratio of PBA-Q76-O16B increased from 0% (i.e. pure NT1-O12B) to 70%
• Tau-ASO The sequence of Tau-ASO was chosen according to the published literature 31 and was synthesized by IDT. Tau-ASO was supplied containing chemical modification with phosphorothioate groups between each nucleic acid and 2 ’ -O -methoxyethyl in the 5 nucleotides on the 5’- and 3’ -termini of ribose to improve efficacy.
• To formulate the ASO for intravenous injection the ASO with the formulated LNP solution is mixed at a weight ratio of 1/15 (ASO to total lipids). Each mouse received five injections of 1 mg/kg ASO, with each injection spaced three days apart.
• mice were sacrificed four days after the last injection, perfused and the brain tissues were harvested and homogenized to extract the total RNA.
• the total tau mRNA levels were analyzed by quantitative PCR.
• Fig. 3C when ASO was delivered using either pure NT1-O14B or pure 306-O12B-3, no tau mRNA reduction in the brain tissues was detected.
• NT1-O14B and 306-012-3 with a w/w ratio of 5:5 and 3:7 displayed tau mRNA reduction in the brain. These two formulations resulted in -25% and -50% mRNA reduction, respectively.
• GFP fused Cre recombinase was chosen as a model protein for the study, using the Ail4 model mouse line (Fig. 4A).
• the Ail4 mouse line contains a flox-stop-flox tdTomato construct.
• the successful intracellular delivery of Cre protein into the cells of Ail4 mouse leads to the gene recombination and turns on the tdTomato expression which can be directly visualized as red fluorescence signal without additional staining.
• (-27)GFP-Cre protein was used.
• NT1-O14B LNPs doped with PBA-Q76-O16B was chosen, as these nanoparticles could successfully deliver (-27)GFP-Cre.
• the weight ratio of NT1-O14B and PBA-Q76-O16B was fixed at 3:7, based on the results observed from the AmB and ASO delivery.
• Lipid formulations were prepared using the approaches described for the formulation for ASO delivery. Briefly, the (-27)GFP-Cre protein was mixed with LNPs at a weight ratio of 1/4 and incubated the solution for 15 min at room temperature before intravenous injection. Mice were injected four times with a dose of 50 ⁇ g protein per injection.
• mice Five days after the last injection, the mice were sacrificed and brain tissues were collected, fixed, and dehydrated. Then the tissues were cryo-sectioned into 15 pm slices and counter-stained with DAPI for fluorescence imaging. As shown in Fig. 4B, strong tdTomato signals were observed in multiple regions of the brain, including cerebral cortex, hippocampus and cerebellum. In contrast, no tdTomato expression in the brain was observed for the mice injected with LNP formulations using either pure NT1-O14B (10:0) or pure PBA-Q76-O16B (0:10). Delivery of different formulation of GFP-Cre fusion protein for sene recombination in the Ai14 mouse brain
• NT1-O14B was doped into various lipid nanoparticle formulations, including 306- O12B, PBA-Q76O16B, Dlin-MC3, to investigate the doped LNP formulation for Cre mRNA delivery into the brain of Ail4 mouse through i.v. injection.
• the weight ratio of NT1-O14B and the other ionizable lipid is 3:7.
• LNP low-density lipoprotein
• co-lipids including (1 ,2-distearoyl-sn-glycero-3- phosphoethanolamine-N- [methoxy(polyethylene glycol)-2000] (DSPE-PEG2000)), cholesterol and DOPE were also included.
• mRNA encoding Cre recombinase was loaded into the LNP, and injected in Ai14 mice. The mice were sacrificed at a specific time point, and brain tissues were collected, fixed, and dehydrated. Then the tissues were cryo- sectioned into 15 pm slices and counter-stained with DAPI for fluorescence imaging.
• the tdTomato signals were observed in multiple regions of the brain, indicating the successful delivery of Cre mRNA into brain cells with such LNP formulation through systemic injection.
• the fluorescence images of section of Ai14 mouse brain were shows in Figs. 19A-19N, Figs. 20A-20B, and Figs. 21A-21B.
• the NT1-O14B doped 306-O12B showed highest brain delivery comparing with that doped in PBA-076O16B or Dlin-MC3 LNP.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Biomedical Technology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Physics & Mathematics (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Optics & Photonics (AREA)
• Nanotechnology (AREA)
• Plant Pathology (AREA)
• Microbiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Biophysics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Steroid Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (12)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=78411889

Family Applications (1)

Country Status (11)

Cited By (5)

Families Citing this family (3)

Citations (2)

Family Cites Families (11)

• 2021
  • 2021-05-04 WO PCT/US2021/030664 patent/WO2021226092A1/en not_active Ceased
  • 2021-05-04 JP JP2022567136A patent/JP7800914B2/ja active Active
  • 2021-05-04 AU AU2021267865A patent/AU2021267865A1/en active Pending
  • 2021-05-04 MX MX2022013865A patent/MX2022013865A/es unknown
  • 2021-05-04 BR BR112022022358A patent/BR112022022358A2/pt unknown
  • 2021-05-04 EP EP21799791.5A patent/EP4146278A4/en active Pending
  • 2021-05-04 CN CN202180047441.5A patent/CN115867262B/zh active Active
  • 2021-05-04 IL IL297869A patent/IL297869A/en unknown
  • 2021-05-04 KR KR1020227042475A patent/KR20230005367A/ko not_active Ceased
  • 2021-05-04 CA CA3177508A patent/CA3177508A1/en active Pending
  • 2021-06-04 US US17/339,563 patent/US11666539B2/en active Active
• 2022
  • 2022-06-13 US US17/838,891 patent/US20220323369A1/en active Pending

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events